Neuropeutics Inc announces a collaboration with LifeArc to develop a new small molecule for the treatment of motor neuron disease (MND), also known as Amyotrophic Lateral Sclerosis (ALS).

Coya Therapeutics is entering into a phase 2b study for its ALS, and the biotech’s CEO believes it’s on the cusp of a game changer.

A 22-month survival benefit was seen for a subset of ALS patients whose disease did not progress when treated with NP001 in ...

The ALS Association will host its second ALS Nexus conference in August, with the goal of making the disease a livable one ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Over the course of the last three years, Brooke Eby — known as "Limpbroozkit" on social media — has documented the ...

Alchemab Therapeutics has entered a collaboration with Lilly to discover novel therapeutic candidates to treat amyotrophic ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...

There's really no guide with ALS. If you were to look at 10 people with this disease in a line, I swear you wouldn't be able to tell whose progression is the fastest and whose is the slowest.